AlphAIAlphAI — Financial news for AI agents
seekingalpha.comOCT 61 min read$NEOG

Neogen outlines FY 2027 revenue of $885M-$890M and adjusted EBITDA of $181M-$183M as Petrifilm transfer nears start (NASDAQ:NEOG)

Neogen (NEOG) outlined FY 2027 revenue of $885M-$890M and adjusted EBITDA of $181M-$183M. CEO Mikhael Nassif described Q1 as showing solid core performance, marking a shift to scaling fundamentals for growth.

Original reporting
seekingalpha.com
Published Oct 6, 2026, 11:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 7, 2026, 1:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$NEOG
Bullish
high confidence
Mentioned
$NEOG
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$NEOGBullishMed
01

Why it matters

The FY 2027 guidance suggests a scaling of operations and improved profitability, which could attract growth‑oriented investors.

02

Market read

First‑report guidance for a small‑cap biotech; modest but material for traders focused on earnings outlooks.

03

What to watch

Execution risk on the Petrifilm transfer and potential competitive pressures.

Relevance 7/10Novelty 7/10Timing: post-market today

Background

Neogen (NASDAQ:NEOG) is a developer of diagnostic solutions for animal health and food safety.

Company-level read

Ticker impact

$NEOGBullishHigh confidence
Context

Neogen disclosed FY 2027 revenue guidance of $885M-$890M and adjusted EBITDA of $181M-$183M.

Expected impact

potential upside as market prices in higher revenue and EBITDA expectations.

Evidence & confidence

The new guidance is a primary disclosure and exceeds prior expectations, likely prompting buying interest.

Market effects

Sector

Sets a higher growth baseline for the animal health diagnostics sector.

Regional

U.S. biotech investors may re‑price similar small‑cap diagnostic firms.

Global

Limited to niche biotech segment; no broad market effect.

Counterpoint

What could challenge this read

If the guidance is already priced in, the stock may face limited upside.

Key entities

  • Executive
    Mikhael Nassif

    CEO of Neogen who presented the guidance.

Read at source← All news

Related articles

OCT 6
$NEOGMedAI 8/10

What Neogen (NEOG) Said on Its Q1 Earnings Call

Neogen (NEOG) reported Q1 adjusted EBITDA of $41.6M, up 170 bps YoY. Adjusted net income was $17.5M, EPS $0.08. Free cash flow improved by $18M. Debt stood at $774M, cash at $172M. The company raised fiscal 2027 revenue guidance to $885M-$890M and adjusted EBITDA to $181M-$183M. It expects margin improvements post-Petrifilm transition and announced a collaboration with Hinalea. The genomics sale is under regulatory review, with proceeds earmarked for debt reduction.

finance.yahoo.com2 min
OCT 6
$NEOGMedAI 8/10

Compared to Estimates, Neogen (NEOG) Q1 Earnings: A Look at Key Metrics

Neogen (NEOG) reported Q1 revenues across various segments, generally meeting or exceeding estimates. Food Safety revenues grew 7.3% YoY to $163.2M, while Animal Safety revenues increased 4.3% YoY to $59.6M. Some segments saw significant changes, such as Animal Safety Genomics Services, up 211.4% YoY, and Food Safety Genomics Services, down 59.6% YoY.

finance.yahoo.com2 min
OCT 6
$NEOGMed

Neogen’s (NASDAQ:NEOG) Q3 CY2026: Strong Sales, Stock Soars

Neogen (NEOG) reported Q3 CY2026 revenue of $222.8M, beating estimates by 7% and growing 6.5% YoY. Adjusted EPS of $0.08 beat estimates by 50%. The company raised full-year revenue guidance to $887.5M and EBITDA guidance to $182M, both above analyst estimates. Operating margin improved to -0.8% from -7.7% YoY, and free cash flow turned positive at $4.7M.

finance.yahoo.com2 min
OCT 6
$PENGHighAI 8/10

After-Hours Movers: PENG, STZ, NEOG

Penguin Solutions (PENG) rose 3% after reporting strong Q4 results and upbeat FY2027 guidance. Constellation Brands (STZ) fell 5% despite Q2 beat, citing lower FY2027 EPS guidance. Neogen (NEOG) surged 8% on Q1 beat and raised FY2027 revenue outlook. PENG: $1.00 adj. EPS, $567M revenue; STZ: $3.74 EPS, $2.63B revenue; NEOG: $0.08 EPS, $222.8M revenue.

investing.com2 min
OCT 6
$NEOGHighAI 8/10

Neogen: Fiscal Q1 Earnings Snapshot

Neogen Corp. (NEOG) reported a fiscal Q1 loss of $11.9 million, or 5 cents per share, but adjusted earnings of 8 cents per share, beating analyst estimates. Revenue was $222.8 million, exceeding expectations. The company forecasts full-year revenue between $885M and $890M.

finance.yahoo.com2 min